A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)

Trial Profile

A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Selumetinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SELECT-2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Apr 2018 Results describing development and validation of joint model for prediction of time to progression using patient data from NCT01750281 and NCT01933932 trials presented at the 109th Annual Meeting of the American Association for Cancer Research
    • 08 Dec 2017 Planned End Date changed from 29 Dec 2017 to 31 Dec 2018.
    • 03 Oct 2017 Primary endpoint (Progression-Free Survival (PFS)) has not been met as per the results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top